(S)-3-(1-氨基乙基)苯酚 | 63720-38-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: (S)-3-(1-氨基乙基)苯酚
• 中文别名: (S)-3-(1-氨基乙基)-苯酚
• 英文名称: 3-hydroxy-(S)-α-phenethylamine
• 英文别名: (S)-1-(3-hydroxyphenyl)ethylamine；(1S)-(3-hydroxyphenyl)ethanamine；1-(3-hydroxy)phenylethanamine；(S)-3-(1-aminoethyl)-phenol；(S)-3-(1-aminoethyl)phenol；3-((S)-1-aminoethyl)phenol；3-[(1S)-1-aminoethyl]phenol
• CAS: 63720-38-7；123982-81-0
• 化学式: C₈H₁₁NO
• mdl: MFCD06761830
• 分子量: 137.181
• InChiKey: WFRNDUQAIZJRPZ-LURJTMIESA-N

物化性质

• 沸点：
  266.3±15.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  (S)-3-(1-氨基乙基)苯酚 在 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三乙胺 、 2-(二叔丁基膦)联苯 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 生成 (S)-[1-(3-morpholin-4-yl-phenyl)ethyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationship of Acrylamides as KCNQ2 Potassium Channel Openers

  摘要：

  A new class of acrylamides was synthesized, and the effects of these analogues on outward potassium current were evaluated by using two electrode voltage clamp recordings from Xenopus laevis oocytes expressing cloned mKCNQ2 channels. SAR studies indicated that the pharmacophore of the acrylamide series includes the (S) absolute configuration at the (1-phenyl)ethyl moiety and the alpha,beta-unsaturated acrylamide functionality with a free NH. This study identified (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide ((S)-1) and (S)-N-[1-(4-fluoro-3morpholin-4-yl-phenyl)-ethyl]-3-(4-fluoro-phenyl)-acrylamide ((S)-2) as KCNQ2 openers for further electrophysiological evaluations. These two acrylamides demonstrated significant activity in the cortical spreading depression model of migraine as we reported previously.

  DOI：

  10.1021/jm0305826
• 作为产物：
  描述：

  3-苄氧基苯乙酮 在 palladium 10% on activated carbon 、 三氯硅烷 、 氢气 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， -20.0~130.0 ℃ 、1.0 MPa 条件下， 反应 74.0h， 生成 (S)-3-(1-氨基乙基)苯酚
  参考文献：
  名称：

  手性亚胺的立体选择性无金属还原批量和流动模式：合成手性活性药物成分的便捷策略

  摘要：

  包含廉价且可移除的手性助剂的亚胺的方便、无金属还原允许合成手性活性药物成分 (API) 的直接前体。该协议是在批量和流动条件下进行的，以提供几乎完全立体控制的高产率的相应产品。在三氯硅烷、一种廉价且无毒的还原剂和非手性路易斯碱（如 N,N-二甲基甲酰胺）的存在下，成功地完成了利凡斯明、拟钙剂 NPS R-568 和 Rho 激酶抑制剂的正式合成。首次在连续流动条件下在微反应器或介观反应器中有效地进行非对映选择性亚胺还原和辅助去除，

  DOI：

  10.1002/ejoc.201601268

文献信息

• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• Quinoline derivatives as nk-3 antagonists
  申请人：——

  公开号：US20040097518A1

  公开（公告）日：2004-05-20

  Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: 1 a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  以下式(I)的某些化合物或其药学上可接受的盐或水合物： 1 制备这些化合物的方法，包含这些化合物的药物组合物以及这些化合物和组合物在医学上的用途。
• [EN] COMPOUNDS WITH NEURAL PROTECTIVE EFFECT, AND PREPARATION AND USE THEREOF<br/>[FR] COMPOSÉS PROTÉGEANT LES NEURONES, PRÉPARATION ET UTILISATION DE CES DERNIERS
  申请人：GUANGZHOU MAGPIE PHARMACEUTICAL CO LTD

  公开号：WO2015109935A1

  公开（公告）日：2015-07-30

  The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.

  该发明通常涉及具有神经保护作用的化合物(I)的公式，以及其制备和用途。这些化合物具有多种机制或功能，例如，抑制单胺氧化酶和胆碱酯酶，清除自由基，并保护神经细胞等细胞。这些化合物可用于制造细胞保护药物，用于预防和/或治疗与单胺氧化酶、胆碱酯酶和自由基相关的疾病，例如，阿尔茨海默病、帕金森病和中风等神经退行性疾病，以及与心脏病、心肌缺血、糖尿病和其他心血管和脑血管疾病相关的自由基相关疾病。
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors
  作者：Jason D. Katz、Andrew Haidle、Kaleen K. Childers、Anna A. Zabierek、James P. Jewell、Yongquan Hou、Michael D. Altman、Alexander Szewczak、Dapeng Chen、Andreas Harsch、Mansuo Hayashi、Lee Warren、Michael Hutton、Hugh Nuthall、Hua-Poo Su、Sanjeev Munshi、Matt G. Stanton、Ian W. Davies、Ben Munoz、Alan Northrup

  DOI：10.1016/j.bmcl.2016.08.068

  日期：2017.1

  The initial structure activity relationships around an isoindoline uHTS hit will be described. Information gleaned from ligand co-crystal structures allowed for rapid refinements in both MARK potency and kinase selectivity. These efforts allowed for the identification of a compound with properties suitable for use as an in vitro tool compound for validation studies on MARK as a viable target for Alzheimer's

  将描述异吲哚啉uHTS命中周围的初始结构活性关系。从配体共晶体结构中收集的信息可以快速完善MARK效能和激酶选择性。这些努力允许鉴定具有适合用作体外工具化合物的性质的化合物，以用于对作为阿尔茨海默氏病可行靶标的MARK进行验证研究。